Clinical Commander

Back to dossier
cardio.atrial_flutter.atrial-septal-defect-related.v1PRODUCTION
cardio.atrial_flutter.atrial-septal-defect-related.v1

Atrial flutter in adult unrepaired/late-repaired atrial septal defect (RA volume overload → CTI macroreentry)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Structural ASD-substrate AFL — typical CTI macroreentry from chronic RA volume overload (L→R shunt). Adult ASD prevalence of AFL: 10-15% by 40 yr / 25-50% by 60 yr (Berger 1999 PMID 10468420). Combined CTI ablation + concurrent ASD closure now standard if hemodynamically significant shunt — AHA/ACC 2018 ACHD (PMID 30121239)

Inputs
2
Actions
0
Advance rule
Set
Advance when

ASD substrate + AFL morphology confirmed

Patient inputs (12)

Adult ASD AFL prevalence rises with age — 10-15% by 40, 25-50% by 60 (Berger 1999 PMID 10468420); CHA2DS2-VASc + ablation candidacy + life expectancy

Conduction ratio variable — ASD-AFL often 2:1 (HR ~150) with right-sided typical CTI circuit; rate control target 80-110

Anchors substrate; ASD type (secundum >> primum/sinus venosus), defect size, Qp/Qs ratio, RV dilation severity, PASP — drives concurrent closure decision per AHA/ACC 2018 ACHD (PMID 30121239)

Sawtooth flutter waves negative in II/III/aVF + positive in V1 (counterclockwise CTI-typical); RBBB or rSR' V1 + right axis + RA enlargement = ASD signature — Saoudi 2001 (PMID 11428013)

DOAC dosing + contrast for ASD device closure + AAD dosing

Reversible cause screen — thyrotoxic flutter overlay common in adult ASD

TTE with agitated saline bubble study — confirms shunt; LA + RA size, RV size + function, PASP, valvular function (mitral cleft if primum ASD), Qp/Qs estimation

SBP <90 with AFL RVR + ASD physiology → emergent DCCV 50-100 J biphasic; ASD shunt may worsen hemodynamic compromise

AC indication identical to AF; LIFELONG typical given persistent RA substrate even after closure — Khairy 2010 GUCH-AF (PMID 20660806)

HAS-BLED + peri-procedure bleed risk for combined closure + ablation

Defines ASD anatomy (rim adequacy for device closure), excludes LAA thrombus pre-CV, identifies sinus venosus or partial anomalous pulmonary venous connection (PAPVC) frequently coexists

Cryptogenic stroke / systemic embolism history → R→L shunt evidence; AC strategy + closure urgency upgraded

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (7)

7 need judgement
  • informationallife_threateningunstable_asd_aflutter_requires_emergent_dccv
    ASD-related atrial flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 50-100 J biphasic now (typical flutter lower energy than AF)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningparadoxical_embolism_with_aflutter_in_asd
    Cryptogenic stroke / TIA / systemic embolism + new AFL in patient with ASD → R→L shunt from RA pressure rise during AFL drives thrombus passage; expedited combined closure + ablation pathway
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningasd_with_eisenmenger_physiology_aflutter
    AFL in patient with ASD and PASP >2/3 systemic, fixed pulmonary HTN, R→L shunt with cyanosis → Eisenmenger; closure CONTRAINDICATED (closure precipitates RV failure and death)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_combined_procedure_device_embolization_or_residual_shunt
    Post-combined procedure: device embolization (very rare ~0.5%, requires emergent surgery), residual significant shunt (>2 mm), atrial perforation with tamponade, or new pulmonary HTN — AHA/ACC 2018 ACHD complications
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereanticoag_continuity_during_combined_procedure
    Periprocedural AC management for combined CTI ablation + ASD device closure — uninterrupted DOAC vs interrupted with bridge; right-sided procedure has lower bleed risk than LA ablation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereamiodarone_toxicity_in_adult_asd_bridge
    New pulmonary infiltrates, thyroid dysfunction (hypo or hyper), or LFT elevation on amiodarone bridge — switch AAD or accept AAD failure → expedite combined procedure
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatemixed_af_aflutter_conversion_in_adult_asd
    Conversion from typical AFL to AF (or AF to AFL) during adult ASD surveillance — mixed substrate present (common given shared RA enlargement)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

ASD-related atrial flutter — rate control + AC + CTI ablation Class I + CONCURRENT ASD device closure if hemodynamically significant — ACC/AHA 2024 (Joglar PMID 38753446); AHA/ACC 2018 ACHD (Stout PMID 30121239)
axis: asd_related_aflutter_combined_closure_ablation_pathway
Selected axis "ASD-related atrial flutter — rate control + AC + CTI ablation Class I + CONCURRENT ASD device closure if hemodynamically significant — ACC/AHA 2024 (Joglar PMID 38753446); AHA/ACC 2018 ACHD (Stout PMID 30121239)" by default fallback (first axis)
  • metoprolol_tartrate
    first line
    beta_blocker
    5 mg IV q5min × 3 then 25-50 mg PO BID • IV/PO • IV q5min × 3 → PO BID
    triggers: asd_aflutter_with_RVR, preserved_RV_function
    AVN slowing for ASD-related AFL — ACC/AHA 2024 (PMID 38753446); preferred over non-DHP CCB if RV dysfunction or pulm HTN
    rxcui 203191
  • metoprolol_succinate
    first line
    beta_blocker
    25-50 mg PO daily; titrate • PO • daily
    triggers: chronic_rate_control_bridge_to_combined_procedure
    Long-acting BB bridge to combined closure + CTI ablation — ACC/AHA 2024
    rxcui 866427
  • amiodarone
    second line
    class_III_AAD
    150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance • IV/PO • load + daily
    triggers: asd_aflutter, structural_heart_disease, rhythm_control_bridge
    Most efficacious AAD bridge to combined procedure given structural substrate; pulm/thyroid/hepatic toxicity monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 703
  • dofetilide
    second line
    class_III_AAD
    125-500 mcg PO BID per CrCl (REMS — inpatient initiation) • PO • BID
    triggers: amiodarone_toxicity_or_intolerance, rhythm_maintenance, baseline_QTc_<440
    Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 49247
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: CHA2DS2VASc_>=2_men_>=3_women, pre_post_cardioversion, pre_post_combined_closure_+_ablation, paradoxical_embolism_history
    AC same as AF; lifelong AC typical given persistent RA substrate post-closure — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978); Khairy 2010 GUCH-AF (PMID 20660806)
    rxcui 1364430
  • rivaroxaban
    second line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15-50) • PO • once daily
    triggers: apixaban_unavailable
    X-VeRT (PMID 24837375); peri-CV / peri-procedural strategy; ENGAGE-AF (PMID 24251369)
    rxcui 1114195
  • dabigatran
    second line
    DOAC_direct_thrombin
    150 mg BID (110 mg BID if age ≥75 or CrCl 30-50 in EU labelling) • PO • BID
    triggers: continuous_DOAC_during_combined_procedure
    Alternative DOAC — reversible with idarucizumab if peri-procedural bleeding
    rxcui 1037045
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    INR 2-3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, DOAC_contraindicated
    Mechanical valve / severe MS — only warfarin — ACC/AHA 2024
    rxcui 11289
  • aspirin
    add on
    antiplatelet_cox1
    81 mg daily lifetime post-device closure; 162-325 mg load if pre-procedure • PO • daily lifetime post-closure
    triggers: post_asd_device_closure
    AHA/ACC 2018 ACHD (PMID 30121239) — ASA lifelong post-device closure for endothelialization + late device-related thrombus prevention
    rxcui 243670
  • clopidogrel
    add on
    P2Y12_inhibitor
    300 mg load → 75 mg daily × 1-6 mo per device • PO • daily × 1-6 mo
    triggers: post_asd_device_closure_dapt_window
    AHA/ACC 2018 ACHD (PMID 30121239) — DAPT 1-6 mo per device label for endothelialization period; resumes single-agent + AC if AC indicated
    rxcui 32968

outpatient playbook — drug actions (3)

  1. 1. continue DOAC lifelong if CHA2DS2-VASc ≥2 or persistent RA enlargement
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc • PO • BID
    trigger: Persistent stroke risk OR persistent RA substrate
    Lifelong AC — ACC/AHA 2024 Class I; Khairy 2010 GUCH-AF (PMID 20660806)
  2. 2. continue amiodarone if rhythm maintenance needed
    rxcui 703
    200 mg PO daily • PO • daily
    trigger: AAD-dependent rhythm maintenance
    Lower recurrence than other AAD — ACC/AHA 2024
  3. 3. continue ASA lifelong post-device
    rxcui 243670
    81 mg PO daily • PO • daily
    trigger: Post-ASD device closure
    AHA/ACC 2018 ACHD (PMID 30121239)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New atrial flutter / palpitations in adult with known unrepaired or late-repaired secundum ASD — RA volume-overload substrate + CTI macroreentry; Atrial flutter on ECG with RV volume-overload pattern (RBBB or rSR' V1, right axis, RA enlargement) — undiagnosed ASD or known ASD presenting with arrhythmia; Palpitations, dyspnea on exertion, or reduced exercise tolerance in adult with systolic flow murmur + fixed split S2 → undiagnosed ASD + new AFL.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter in adult unrepaired/late-repaired atrial septal defect (RA volume overload → CTI macroreentry)** (cardio.atrial_flutter.atrial-septal-defect-related.v1).
Scope: Structural ASD-substrate AFL — typical CTI macroreentry from chronic RA volume overload (L→R shunt). Adult ASD prevalence of AFL: 10-15% by 40 yr / 25-50% by 60 yr (Berger 1999 PMID 10468420). Combined CTI ablation + concurrent ASD closure now standard if hemodynamically significant shunt — AHA/ACC 2018 ACHD (PMID 30121239)

No severity triggers fired against current inputs.

Plan

Regimen axis: **ASD-related atrial flutter — rate control + AC + CTI ablation Class I + CONCURRENT ASD device closure if hemodynamically significant — ACC/AHA 2024 (Joglar PMID 38753446); AHA/ACC 2018 ACHD (Stout PMID 30121239)**.
1. metoprolol_tartrate 5 mg IV q5min × 3 then 25-50 mg PO BID IV/PO IV q5min × 3 → PO BID (beta_blocker, first line) — AVN slowing for ASD-related AFL — ACC/AHA 2024 (PMID 38753446); preferred over non-DHP CCB if RV dysfunction or pulm HTN
2. metoprolol_succinate 25-50 mg PO daily; titrate PO daily (beta_blocker, first line) — Long-acting BB bridge to combined closure + CTI ablation — ACC/AHA 2024
3. amiodarone 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance IV/PO load + daily (class_III_AAD, second line) — Most efficacious AAD bridge to combined procedure given structural substrate; pulm/thyroid/hepatic toxicity monitoring — ACC/AHA 2024 (PMID 38753446)
4. dofetilide 125-500 mcg PO BID per CrCl (REMS — inpatient initiation) PO BID (class_III_AAD, second line) — Alternative to amiodarone; dofetilide REMS — must be initiated inpatient with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
5. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — AC same as AF; lifelong AC typical given persistent RA substrate post-closure — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978); Khairy 2010 GUCH-AF (PMID 20660806)
6. rivaroxaban 20 mg with food (15 mg if CrCl 15-50) PO once daily (DOAC_factor_Xa, second line) — X-VeRT (PMID 24837375); peri-CV / peri-procedural strategy; ENGAGE-AF (PMID 24251369)
7. dabigatran 150 mg BID (110 mg BID if age ≥75 or CrCl 30-50 in EU labelling) PO BID (DOAC_direct_thrombin, second line) — Alternative DOAC — reversible with idarucizumab if peri-procedural bleeding
8. warfarin INR 2-3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS — only warfarin — ACC/AHA 2024
9. aspirin 81 mg daily lifetime post-device closure; 162-325 mg load if pre-procedure PO daily lifetime post-closure (antiplatelet_cox1, add on) — AHA/ACC 2018 ACHD (PMID 30121239) — ASA lifelong post-device closure for endothelialization + late device-related thrombus prevention
10. clopidogrel 300 mg load → 75 mg daily × 1-6 mo per device PO daily × 1-6 mo (P2Y12_inhibitor, add on) — AHA/ACC 2018 ACHD (PMID 30121239) — DAPT 1-6 mo per device label for endothelialization period; resumes single-agent + AC if AC indicated

Setting playbook (outpatient) — Long-term post-combined-procedure ACHD surveillance, lifelong AC if persistent RA enlargement, AAD continuation if rhythm maintenance needed, recurrence + concomitant-AF screening, late residual-shunt surveillance, transition to / continuation of adult ACHD care — ACC/AHA 2024 (PMID 38753446); AHA/ACC 2018 ACHD (PMID 30121239)
11. continue DOAC lifelong if CHA2DS2-VASc ≥2 or persistent RA enlargement apixaban 5 mg BID per CHA2DS2-VASc PO BID — Persistent stroke risk OR persistent RA substrate (Lifelong AC — ACC/AHA 2024 Class I; Khairy 2010 GUCH-AF (PMID 20660806))
12. continue amiodarone if rhythm maintenance needed 200 mg PO daily PO daily — AAD-dependent rhythm maintenance (Lower recurrence than other AAD — ACC/AHA 2024)
13. continue ASA lifelong post-device 81 mg PO daily PO daily — Post-ASD device closure (AHA/ACC 2018 ACHD (PMID 30121239))

Non-pharmacologic actions:
- Lifestyle: weight, alcohol limit, OSA treatment, exercise (ACC/AHA 2024)
- Vaccinations + secondary prevention bundle (ACC/AHA 2024)
- Annual ACHD review for repeat ablation consideration if recurrence or new-onset AF
- Endocarditis prophylaxis × 6 months post-closure then per ACHD complexity (AHA/ACC 2018 ACHD)
- Pregnancy + family planning counseling — ACHD pregnancy is high-risk; closure timing relative to conception planning required

AVOID / contraindication checks:
- Asd closure contraindicated if eisenmenger or fixed pulm htn PASP >2/3 systemic — AHA/ACC 2018 ACHD (PMID 30121239)
- Flecainide propafenone block if structural heart disease — ASD substrate is inherently structural
- Dofetilide REMS inpatient initiation — ACC/AHA 2024 (PMID 38753446)
- Amiodarone monitor pulm thyroid LFT — ACC/AHA 2024
- Non DHP CCB block if EF lt 40 or RV dysfunction or pulm HTN — ACC/AHA 2024
- Combined closure ablation requires LAA thrombus exclusion via TEE pre procedure if AC not uninterrupted 3wk
- DOAC renal dose adjustment — ESC 2024 (PMID 39050851)
- NEVER interrupt AC without bridge — interruption is leading thrombosis trigger in adult ASD with prior paradoxical embolism
- Device DAPT vs triple therapy bleeding risk balance — case by case if AC indication concurrent with device closure DAPT window

Monitoring

Regimen monitoring:
- telemetry continuous acute — ACC/AHA 2024
- HR target 80-110 pre combined procedure — ACC/AHA 2024
- QTc serial dofetilide sotalol amiodarone — ACC/AHA 2024
- PFTs TFTs LFTs baseline then q6m on amiodarone — ACC/AHA 2024
- lifelong AC due to persistent RA substrate post-closure — ACC/AHA 2024 + Khairy 2010 GUCH-AF (PMID 20660806)
- post-combined-procedure groin hematoma + device embolization surveillance × 24h — AHA/ACC 2018 ACHD
- TTE at 6 weeks + 6 mo post-closure for residual shunt + device position — AHA/ACC 2018 ACHD (PMID 30121239)
- post-procedure 4-week ECG + Holter 3-6-12 mo for AF AFL recurrence
- INR q week during warfarin initiation when used

Setting (outpatient) monitoring:
- ACHD q3-6 mo first year then annually (AHA/ACC 2018 ACHD)
- Holter at 3, 6, 12 mo post-procedure (Calkins 2007)
- Annual TTE — RA + RV + PASP + residual shunt + device position (AHA/ACC 2018 ACHD)
- Annual TFTs / LFTs / PFTs on amiodarone (ACC/AHA 2024)
- CBC + eGFR q6m on DOAC (ESC 2024)

Follow-up plan: ACHD clinic + EP at 4 weeks post-procedure with 12-lead + Holter; AC continuation lifelong if persistent RA enlargement (substrate persistence — Silversides 2004 PMID 15036666); device endothelialization period 6 months — DAPT 1-6 mo per device + ASA lifetime; lifestyle (alcohol, weight, OSA per LEGACY); 3, 6, 12-month Holter; transition pediatric ACHD → adult ACHD if not yet established
- Close-out criterion: Follow-up booked + ACHD pathway entered

Monitoring phase: Telemetry; QTc on dofetilide / sotalol / amiodarone; post-combined-procedure observation for groin hematoma, tamponade, device embolization (rare ~0.5%), atrioesophageal fistula (lower risk for right-sided CTI vs LA lines); AC adherence

Disposition

Current setting: outpatient — Long-term post-combined-procedure ACHD surveillance, lifelong AC if persistent RA enlargement, AAD continuation if rhythm maintenance needed, recurrence + concomitant-AF screening, late residual-shunt surveillance, transition to / continuation of adult ACHD care — ACC/AHA 2024 (PMID 38753446); AHA/ACC 2018 ACHD (PMID 30121239)

Disposition criteria:
- Continue chronic ACHD surveillance with this engine; cross-link to cardio.afib.core.v1 if AF predominant; cross-link to cardio.atrial_flutter.adult-congenital-heart-disease.v1 if broader CHD substrate develops

Escalation triggers (move to higher acuity):
- Recurrent ASD-AFL despite combined procedure → repeat EP mapping (Calkins 2007)
- New AF detected → AF management via cardio.afib.core.v1
- Amiodarone toxicity (pulm fibrosis, thyroid, LFT) → switch to dofetilide or repeat ablation — ACC/AHA 2024
- Stroke / TIA on AC → workup + reassess regimen — ACC/AHA 2024
- Late residual significant shunt or device complication → ACHD reassessment
- New pulmonary HTN on annual TTE → RHC + ACHD pulm-HTN pathway

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] ASD-related atrial flutter with SBP <90, AMS, ongoing ischemia, or pulmonary edema → synchronized DCCV 50-100 J biphasic now (typical flutter lower energy than AF)
- [LIFE_THREATENING] Cryptogenic stroke / TIA / systemic embolism + new AFL in patient with ASD → R→L shunt from RA pressure rise during AFL drives thrombus passage; expedited combined closure + ablation pathway
- [LIFE_THREATENING] AFL in patient with ASD and PASP >2/3 systemic, fixed pulmonary HTN, R→L shunt with cyanosis → Eisenmenger; closure CONTRAINDICATED (closure precipitates RV failure and death)

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); 2018 AHA/ACC Adult Congenital Heart Disease Guideline (Stout PMID 30121239); ESC 2020 ACHD Guideline (Baumgartner PMID 32860412) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 30121239) [PMID:30121239](https://pubmed.ncbi.nlm.nih.gov/30121239/)
- Cited evidence (PMID 32860412) [PMID:32860412](https://pubmed.ncbi.nlm.nih.gov/32860412/)
- Cited evidence (PMID 15036666) [PMID:15036666](https://pubmed.ncbi.nlm.nih.gov/15036666/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); 2018 AHA/ACC Adult Congenital Heart Disease Guideline (Stout PMID 30121239); ESC 2020 ACHD Guideline (Baumgartner PMID 32860412) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 30121239) — PMID:30121239
  • Cited evidence (PMID 32860412) — PMID:32860412
  • Cited evidence (PMID 15036666) — PMID:15036666